Familial thrombocythaemia - a distinct entity from essential thrombocythaemia.
作者信息
Bussel James, Kucine Nicole
机构信息
Pediatric Hematology-Oncology, Weill-Cornell Medical College, New York, NY, USA.
Pediatrics, Weill-Cornell Medical College, New York, NY, USA.
出版信息
Br J Haematol. 2021 Sep;194(5):808-809. doi: 10.1111/bjh.17701. Epub 2021 Aug 2.
Abstract
摘要
相似文献
1
Familial thrombocythaemia - a distinct entity from essential thrombocythaemia.家族性血小板增多症——一种与原发性血小板增多症不同的疾病实体。
Br J Haematol. 2021 Sep;194(5):808-809. doi: 10.1111/bjh.17701. Epub 2021 Aug 2.
2
CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.CALR与JAK2突变的原发性血小板增多症——141例患者的报告
Br J Haematol. 2015 Jan;168(1):151-3. doi: 10.1111/bjh.13076. Epub 2014 Aug 8.
3
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.英国血液学标准委员会原发性血小板增多症诊断标准的修订
Br J Haematol. 2014 Nov;167(3):421-3. doi: 10.1111/bjh.12986. Epub 2014 Jun 17.
4
Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.慢性粒细胞白血病中的血小板增多症和STAT5激活与JAK2 V617F或钙网蛋白突变无关。
J Clin Pathol. 2016 Aug;69(8):713-9. doi: 10.1136/jclinpath-2015-203498. Epub 2016 Jan 11.
5
Novel CALR somatic mutations in essential thrombocythaemia.
Br J Haematol. 2016 Jun;173(5):797-801. doi: 10.1111/bjh.13638. Epub 2015 Sep 7.
6
A rare CALR variant mutation and a review of CALR in essential thrombocythemia.CALR 罕见变异突变及 CALR 在原发性血小板增多症中的作用综述
J Thromb Thrombolysis. 2018 Apr;45(3):457-462. doi: 10.1007/s11239-018-1619-0.
7
JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.原发性血小板增多症患者的JAK2V617F、CALR和MPL突变与骨髓组织学
Acta Haematol. 2018;140(4):234-239. doi: 10.1159/000493970. Epub 2018 Nov 7.
8
Low incidence of familial occurrence of thrombocythaemia and/or thrombocytosis.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(5):695-9.
9
Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.血小板生成素检测作为小儿血小板增多症评估的关键组成部分
Pediatr Blood Cancer. 2016 Aug;63(8):1484-7. doi: 10.1002/pbc.26032. Epub 2016 Apr 21.
10
Thrombocytosis.
JAMA. 2015 Sep 15;314(11):1171-2. doi: 10.1001/jama.2015.8515.
引用本文的文献
1
[Advances in the diagnosis and treatment of thrombocytosis in children].[儿童血小板增多症的诊断与治疗进展]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Feb 15;27(2):236-241. doi: 10.7499/j.issn.1008-8830.2408066.
本文引用的文献
1
Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients.骨髓增殖性白血病病毒癌基因（MPL）突变相关家族性血小板增多症的临床病程：64 例儿科和成人患者的综述。
Br J Haematol. 2021 Sep;194(5):893-898. doi: 10.1111/bjh.17624. Epub 2021 Jun 15.
2
Population structure of indigenous inhabitants of Arabia.阿拉伯原住民的人口结构。
PLoS Genet. 2021 Jan 11;17(1):e1009210. doi: 10.1371/journal.pgen.1009210. eCollection 2021 Jan.
3
Diagnostic workflow for hereditary erythrocytosis and thrombocytosis.遗传性红细胞增多症和血小板增多症的诊断流程。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):391-396. doi: 10.1182/hematology.2019000047.
4
Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.20 岁以下被诊断为原发性血小板增多症或真性红细胞增多症患者的特征和结局：系统评价。
Haematologica. 2019 Aug;104(8):1580-1588. doi: 10.3324/haematol.2018.200832. Epub 2019 Jan 24.
5
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.对骨髓增殖性肿瘤患者血栓形成事件病因的新见解增加了新型治疗方法的可能性。
Haematologica. 2019 Jan;104(1):3-6. doi: 10.3324/haematol.2018.205989.
6
MPL-mutated essential thrombocythemia: a morphologic reappraisal.MPL 突变的原发性血小板增多症：形态学再评估
Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3.
7
Essential thrombocythaemia with mutation in : clinicopathological correlation and comparison with 2V617F-mutated and mutated genotypes.伴有 JAK2 V617F 突变的原发性血小板增多症：临床病理相关性及与 JAK2 V617F 突变和突变基因型的比较
J Clin Pathol. 2018 Nov;71(11):975-980. doi: 10.1136/jclinpath-2018-205227. Epub 2018 Jun 22.
8
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.NCCN 指南解读：骨髓增殖性肿瘤，第 2.2018 版。
J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.
9
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.评估基因组时代原发性血小板增多症患者的血栓形成风险。
Leukemia. 2017 Sep;31(9):1845-1854. doi: 10.1038/leu.2017.150. Epub 2017 May 22.
10
Advances in understanding the pathogenesis of familial thrombocythaemia.家族性血小板增多症发病机制的研究进展。
Br J Haematol. 2011 Mar;152(6):701-12. doi: 10.1111/j.1365-2141.2010.08500.x. Epub 2011 Feb 8.
Zotero 插件